Enhancing the QUAlity and Transparency Of health Research
Search for reporting guidelines
Use your browser's Back button to return to your search results
Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit
| Reporting guideline provided for? (i.e. exactly what the authors state in the paper) |
Reporting of rheumatic and musculoskeletal disease (RMD) exercise trials. |
| Full bibliographic reference | Metsios GS, Brodin N, Vlieland TPMV, Van den Ende CHM, Stavropoulos-Kalinoglou A, Fatouros I, van der Esch M, Fenton SAM, Tzika K, Moe RH, van Zanten JJCSV, Koutedakis Y, Swinnen TW, Veskoukis AS, Boström C, Kennedy N, Nikiphorou E, Fragoulis GE, Niedermann K, Kitas GD; IMPACT-RMD Consortium. Position Statement on Exercise Dosage in Rheumatic and Musculoskeletal Diseases: The Role of the IMPACT-RMD Toolkit. Mediterr J Rheumatol. 2021;32(4):378-385. |
| Language | English |
| PubMed ID | 35128335 |
| Relevant URLs (full-text if available) |
Read the full-text of this reporting guideline. |
| Reporting guideline acronym | IMPACT-RMD Toolkit |
| Study design | Clinical trials, Experimental studies |
| Clinical area | Rheumatology |
| Applies to the whole report or to individual sections of the report? | Intervention (exposure) |
| Record last updated on | May 20, 2022 |